Physical model evaluation of topical prodrug delivery-simultaneous transport and bioconversion of vidarabine-5'-valerate I: Physical model development
A physical model approach to the topical delivery of a vidarabine ester prodrug was investigated. It involved modeling, theoretical simulations, experimental method development for factoring and quantifying parameters, and, finally, employment of the deduced parameters to determine the steady-state...
Saved in:
Published in: | Journal of pharmaceutical sciences Vol. 68; no. 11; p. 1341 |
---|---|
Main Authors: | , , , |
Format: | Journal Article |
Language: | English |
Published: |
United States
01-11-1979
|
Subjects: | |
Online Access: | Get more information |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | A physical model approach to the topical delivery of a vidarabine ester prodrug was investigated. It involved modeling, theoretical simulations, experimental method development for factoring and quantifying parameters, and, finally, employment of the deduced parameters to determine the steady-state species fluxes and concentration profiles in the target tissue. The present report describes the physical modeling and theoretical simulation aspects. The physical model for the simultaneous transport and bioconversion of a topically delivered prodrug was formulated assuming homogeneous enzyme distributions and constant diffusivities in the membrane. The mathematical problem was solved, and the solution yielded concentration profiles and fluxes of all species in the biomembrane. These results provided the prevailing levels of the prodrug, the drug, and the metabolite at the target site and the transport rates of all species into the bloodstream. Computations of concentration profiles and fluxes were carried out for a reasonable range of the parameters. The relative activities of the esterase and the deaminase enzymes, as well as the stratum corneum permeabilities, were important in influencing the concentration profiles and fluxes of all species. |
---|---|
AbstractList | A physical model approach to the topical delivery of a vidarabine ester prodrug was investigated. It involved modeling, theoretical simulations, experimental method development for factoring and quantifying parameters, and, finally, employment of the deduced parameters to determine the steady-state species fluxes and concentration profiles in the target tissue. The present report describes the physical modeling and theoretical simulation aspects. The physical model for the simultaneous transport and bioconversion of a topically delivered prodrug was formulated assuming homogeneous enzyme distributions and constant diffusivities in the membrane. The mathematical problem was solved, and the solution yielded concentration profiles and fluxes of all species in the biomembrane. These results provided the prevailing levels of the prodrug, the drug, and the metabolite at the target site and the transport rates of all species into the bloodstream. Computations of concentration profiles and fluxes were carried out for a reasonable range of the parameters. The relative activities of the esterase and the deaminase enzymes, as well as the stratum corneum permeabilities, were important in influencing the concentration profiles and fluxes of all species. |
Author | Yu, C D Higuchi, W I Fox, J L Ho, N F |
Author_xml | – sequence: 1 givenname: C D surname: Yu fullname: Yu, C D – sequence: 2 givenname: J L surname: Fox fullname: Fox, J L – sequence: 3 givenname: N F surname: Ho fullname: Ho, N F – sequence: 4 givenname: W I surname: Higuchi fullname: Higuchi, W I |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/512880$$D View this record in MEDLINE/PubMed |
BookMark | eNpdkD1PwzAYhD2Uj7awMjF4Y0qxHduJ2VDFR6VKMMBcOfEbcJXYke1E6h_h9xLRTkwn3Z2ek26BZs47QOiGkhUlhN3v-7hikhBZUkr4DM0nk2W54OoSLWLckykiQlygc0FZWZI5-nn_PkRb6xZ33kCLYdTtoJP1DvsGJ9__ZX3wJgxfeGrYEcIhi7Yb2qQd-CHiFLSLvQ8Ja2dwZX3t3dSKJ8hojQ66sg4ycZdNfAg6Ad484H_bBkZofd-BS1forNFthOuTLtHn89PH-jXbvr1s1o_brM455ZlRVS6kkFCWGjRlhQCoFWeiyJnkVDZCKWhqTkVTNXmlmlxqplhBOSkk45wt0e2R2w9VB2bXB9vpcNgd72G_2WpqMQ |
CitedBy_id | crossref_primary_10_1002_jps_21594 crossref_primary_10_1016_0378_5173_89_90270_6 crossref_primary_10_1016_j_jconrel_2004_03_020 crossref_primary_10_1016_0168_3659_87_90059_9 crossref_primary_10_1016_0378_5173_93_90405_5 crossref_primary_10_1016_0378_5173_83_90145_X crossref_primary_10_3109_03602539009041089 crossref_primary_10_1002_jps_2600720620 crossref_primary_10_1016_j_addr_2012_10_009 crossref_primary_10_1002_jps_2600750104 crossref_primary_10_1016_0378_5173_88_90055_5 crossref_primary_10_1016_0378_5173_86_90179_1 crossref_primary_10_1081_CUS_120001859 crossref_primary_10_1002_jps_2600841215 crossref_primary_10_1007_s11095_006_9781_z crossref_primary_10_1016_S0928_0987_97_00068_7 crossref_primary_10_3109_03639049409038326 crossref_primary_10_3109_00498258709043943 crossref_primary_10_1016_0168_3659_94_00101_Y crossref_primary_10_1016_0378_5173_94_90297_6 crossref_primary_10_1002_jps_2600810112 crossref_primary_10_1016_j_jconrel_2006_04_003 crossref_primary_10_1016_0168_3659_87_90009_5 crossref_primary_10_1016_S0022_5193_89_80174_2 crossref_primary_10_1016_0378_5173_85_90107_3 crossref_primary_10_1007_BF03190197 crossref_primary_10_1007_s11095_005_4593_0 crossref_primary_10_1159_000351926 crossref_primary_10_1016_S0939_6411_97_00060_X crossref_primary_10_1002_jps_10239 crossref_primary_10_1002_jps_2600681105 crossref_primary_10_1016_S0169_409X_03_00118_2 crossref_primary_10_1016_j_ajps_2017_01_005 crossref_primary_10_1111_j_2042_7158_1994_tb03251_x crossref_primary_10_1016_0168_3659_85_90037_9 crossref_primary_10_1016_0378_5173_94_90245_3 crossref_primary_10_1016_0025_5564_93_90048_F crossref_primary_10_1002_jps_2600841114 crossref_primary_10_1016_0378_5173_90_90142_Q crossref_primary_10_1016_0378_5173_90_90174_3 crossref_primary_10_1016_0378_5173_87_90194_3 crossref_primary_10_1016_j_ijpharm_2017_04_030 crossref_primary_10_1016_0168_3659_87_90067_8 crossref_primary_10_1016_0378_5173_82_90048_5 crossref_primary_10_1002_jps_2600750221 crossref_primary_10_1016_0378_5173_90_90184_6 crossref_primary_10_1002_jps_2600731120 crossref_primary_10_1002_jps_2600690708 crossref_primary_10_1002_jps_2600690707 crossref_primary_10_1006_jtbi_2000_2023 crossref_primary_10_1111_1523_1747_ep12277361 crossref_primary_10_1007_BF01061849 crossref_primary_10_1002_jps_2600730706 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1002/jps.2600681104 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology Mathematics |
ExternalDocumentID | 512880 |
Genre | Research Support, U.S. Gov't, P.H.S Journal Article |
GroupedDBID | --- -~X .3N .GA .GJ .Y3 05W 0R~ 10A 1CY 1L6 1OB 1OC 1ZS 31~ 33P 36B 3O- 3WU 4.4 457 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52S 52T 52W 52X 53G 5GY 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A03 A8Z AAEVG AAHHS AAKUH AALRI AAOIN AAONW AAXUO AAYOK AAZKR ABCQN ABEML ABFRF ABIJN ABJNI ABMAC ABOCM ABPVW ACBWZ ACCFJ ACGFO ACGFS ACIWK ACPRK ACSCC ACXQS ADBBV ADIZJ ADVLN AEEZP AEFWE AEIMD AENEX AEQDE AEUQT AFBPY AFFNX AFJKZ AFRAH AFTJW AFZJQ AGHFR AI. AITUG AIWBW AJAOE AJBDE AKRWK ALAGY ALMA_UNASSIGNED_HOLDINGS AMBMR AMRAJ ATUGU AZBYB BAFTC BDRZF BNHUX BROTX BRXPI BY8 CGR CS3 CUY CVF D-E D-F DCZOG DPXWK DR2 DU5 E3Z EBD EBS ECM EIF EJD EMB EMOBN ESTFP F00 F01 F04 F5P FDB FEDTE G-S G.N GNP GODZA H.T H.X HBH HF~ HHY HHZ HOLLA HVGLF HX~ HZ~ IX1 J0M JPC KQQ L7B LAW LC2 LC3 LH4 LP6 LP7 LSO LW6 M41 M6Q MK0 MK4 N04 N05 N9A NF~ NNB NPM O66 O9- OIG P2P P2X P4D Q.N Q11 QB0 QRW R.K RNS ROL RWI RX1 RYL SSZ SUPJJ SV3 UB1 UKR UNMZH V2E V8K VH1 W8V W99 WBFHL WH7 WIB WJL WQJ WRC WUP WWP WYUIH XG1 XPP XV2 Y6R YCJ ZE2 ZGI ZXP ~IA ~WT |
ID | FETCH-LOGICAL-c3414-d9b35656e88aea1275eec94257326416f599efc415fbf3b9f36a2927140762442 |
ISSN | 0022-3549 |
IngestDate | Sat Sep 28 08:38:19 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 11 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c3414-d9b35656e88aea1275eec94257326416f599efc415fbf3b9f36a2927140762442 |
PMID | 512880 |
ParticipantIDs | pubmed_primary_512880 |
PublicationCentury | 1900 |
PublicationDate | November 1979 |
PublicationDateYYYYMMDD | 1979-11-01 |
PublicationDate_xml | – month: 11 year: 1979 text: November 1979 |
PublicationDecade | 1970 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Journal of pharmaceutical sciences |
PublicationTitleAlternate | J Pharm Sci |
PublicationYear | 1979 |
SSID | ssj0006055 |
Score | 1.3844247 |
Snippet | A physical model approach to the topical delivery of a vidarabine ester prodrug was investigated. It involved modeling, theoretical simulations, experimental... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 1341 |
SubjectTerms | Administration, Topical Animals Biological Transport In Vitro Techniques Mathematics Mice Mice, Nude Models, Biological Skin - ultrastructure Skin Absorption Valerates - metabolism Vidarabine - administration & dosage Vidarabine - analogs & derivatives Vidarabine - metabolism |
Title | Physical model evaluation of topical prodrug delivery-simultaneous transport and bioconversion of vidarabine-5'-valerate I: Physical model development |
URI | https://www.ncbi.nlm.nih.gov/pubmed/512880 |
Volume | 68 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1NbxMxELUS4NAeEJQiWgryAdpDaprsR2L3hkpQitQqUoMEp8q7tksqNVl1G6T8EX4vM7Z3vYlaBAcuq5W9sjc7T-OZycwbQt7FXdU1KhMsVlnCEiMM49lAMh3nGfg9xiQ2N2d0MTj_xj8Nk2GrVTUtDWP_VdIwBrLGytl_kHa9KAzAPcgcriB1uP6V3MfVh7c9bhps3jYbYF7YOVSbt4urDjyBeRlLVk4xs1DONGbE3lWE5_afhWw6t6npNq6Gi_ycKnkrwaPWLH0fDRjsgMzMunOK4YW1_VVISnrADi5-rETV_ZFcm_rfFzaWGzKT_Xn5pRPC5jbcex6SlEfTK-zxYvMHfVhYuUq_gfAVfg1lbQsNHKNppaz7vAnKXkP1IjPdvWeC45i9LsoPSMbf5z3f8LgBhuLGogGMH-76Sv1pbo2f2020SRtsLTTHT85qSwBcxbRmq4cfUpGGdqOj1dfZIE_cMmvOjTVyJs_IUy8V-tHB6jlp6dkW2TyrqX3LLbI_dvJaHtJJqN0rD-k-HQca9OUL8qtCArVIoAGJdG6oRyL1SKT3IpHWSKSARLqCRFykicSDGof09Jiu7d1A4Tb5-nk4ORkx3wWE5SDRhCmRxeh1aM6lltiPQOtc4FEDnge4EyYVQpscDFGTmTgTJu7LSERIRAkHfZJEL8mj2XymXxHKUylTrVQ3lTrR4Hj3o1wjg5-Je3Ev5ztk2339y8JRvVw6qew-MP6abATg7pHHBnSIfkPapVq8tUj4DYXQl2s |
link.rule.ids | 782 |
linkProvider | EBSCOhost |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Physical+model+evaluation+of+topical+prodrug+delivery-simultaneous+transport+and+bioconversion+of+vidarabine-5%27-valerate+I%3A+Physical+model+development&rft.jtitle=Journal+of+pharmaceutical+sciences&rft.au=Yu%2C+C+D&rft.au=Fox%2C+J+L&rft.au=Ho%2C+N+F&rft.au=Higuchi%2C+W+I&rft.date=1979-11-01&rft.issn=0022-3549&rft.volume=68&rft.issue=11&rft.spage=1341&rft_id=info:doi/10.1002%2Fjps.2600681104&rft_id=info%3Apmid%2F512880&rft_id=info%3Apmid%2F512880&rft.externalDocID=512880 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-3549&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-3549&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-3549&client=summon |